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Purpose: Hemiplegic shoulder pain (HSP) is the most common pain condition after stroke. 
Pulsed radiofrequency (PRF) treatment of the suprascapular nerve (SSN) effectively relieves 
shoulder pain conditions. To date, there is no study about the effects of PRF treatment for HSP. 
Thus, our aim was to report on a case series about its use in chronic stroke.
Patients and methods: Six chronic stroke patients with HSP (visual analog scale [VAS] score for 
pain ≥30 mm) underwent ultrasound-guided SSN PRF treatment. All were evaluated before treatment 
and at 4 and 16 weeks of follow-up. The main outcome was VAS score. Secondary outcomes were 
Modified Ashworth Scale, shoulder passive range of motion (PROM), Disability Assessment Scale 
(DAS), Fugl-Meyer Assessment, and EuroQol-5 dimension questionnaire (EuroQol-5D) scores.
Results: As compared with baseline, improvement was observed in the following parameters: 
VAS for pain (at 4 weeks, P=0.023; at 16 weeks, P=0.023); shoulder PROM for abduction (at 
4 weeks, P=0.023; at 16 weeks, P=0.024), flexion (at 4 and 16 weeks, P=0.024), extension (at 
4 and 16 weeks, P=0.02), and external rotation (4 and 16 weeks, P=0.02); DAS for hygiene 
(at 4 and 16 weeks, P=0.024), dressing (at 4 weeks, P=0.02; at 16 weeks, P=0.024), and pain 
(at 4 weeks, P=0.024; at 16 weeks, P=0.023); and EuroQol-5D (at 4 and 16 weeks, P=0.024).
Conclusion: Our observations support the use of ultrasound-guided SSN PRF treatment for 
HSP in chronic stroke patients.
Keywords: chronic pain, pain management, rehabilitation
Introduction
Hemiplegic shoulder pain (HSP) is the most common pain condition in stroke 
patients and a major contributor to poststroke disability.1,2 Its multifactorial etiology 
includes impaired motor function (muscle tone changes), soft tissue lesions (rota-
tor cuff and biceps tendon disorders, adhesive capsulitis), and altered peripheral 
or central nervous system (CNS) activity (complex regional pain syndrome type 
1, peripheral nerve entrapment, neglect, sensory impairment, central pain, central 
sensitization).3,4
Radiofrequency treatments are offered for various pain syndromes according to the 
assumption that selectively heating nervous structures can impede nociceptive input.5 
From a technical point of view, they can be delivered using a continuous modality or a 
pulsed one.5,6 Continuous radiofrequency (CRF) is a neurolytic technique that applies 
heat for selective destruction of pain-carrying nerve fibers (A-δ and C fibers).5 It uses a 
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constant high-frequency alternating current to induce coagu-
lative necrosis at the target tissue by producing temperatures 
≥45°C.6 Considering the possible adverse events of CRF 
neuroablation (eg, lasting motor deficits, neuritis and deaffer-
entation pain), pulsed radiofrequency (PRF) was developed as 
an alternative modality that uses short, high-voltage current 
bursts to obtain more reversible and less destructive effects 
than CRF.5–7 As to the mechanism of action of PRF, to date, 
most studies point toward a neuromodulatory-type effect 
based on an alteration in synaptic transmission.8,9 However, 
there is an ongoing discussion about the lesioning effect of 
PRF. In particular, Cosman and Cosman10 and Cosman et al11 
reported that PRF produces heat bursts (with temperatures 
in the range) associated with destructive heat lesions (whose 
size is affected also by the tip gage, tip length, and time). 
Nevertheless, PRF has demonstrated a remarkable margin 
of safety.9
To provide pain relief and facilitate rehabilitation of 
patients with shoulder pain, physicians often perform supra-
scapular nerve (SSN) block as a useful management in vari-
ous conditions.12–16 This can be done by means of analgesics, 
corticosteroid, and electrical stimulation techniques.14,15 As 
to the use of SSN PRF treatment for shoulder pain, a good 
clinical efficacy lasting for 6 months with scant complications 
has been reported in the literature.17,18
With regard to patients with stroke, the SSN block 
injection with corticosteroid and anesthetic was found to be 
effective and safe for the treatment of HSP.19 Even if this is 
in line also with our daily practice, we have a growing clini-
cal experience concerning the use of SSN PRF treatment 
for HSP in order to obtain more stable and long-lasting 
effects. Unfortunately, to date, there is no study on it. Thus, 
our aim was to report on a case series about the effects of 
ultrasound-guided SSN PRF treatment in chronic stroke 
patients with HSP.
Patients and methods
This single-center, retrospective, chart review case series 
analyzed data from six chronic stroke patients with HSP who 
had undergone ultrasound-guided SSN PRF treatment at our 
Clinical Unit from February 2017 to June 2017.
The inclusion criteria were age ≥18 years, first-ever 
unilateral stroke, Mini Mental State Examination ≥24,20 
HSP ≥30 mm on the visual analog scale (VAS),21 time since 
stroke >6 months, and time since last botulinum toxin treat-
ment >6 months. The exclusion criteria were participation in 
other trials, change in pain medication during the follow-up 
period, aphasia, neurolytic or surgical procedures for upper 
limb spasticity, and other conditions at the affected shoulder 
(rotator cuff disorders, frozen shoulder, thoracic outlet syn-
drome, osteoarthritis, bursitis, recent trauma, bone fracture, 
joint replacement).
All participants were outpatients. All patients provided 
written informed consent, which included consent for data 
extraction from chart review as needed. The study was carried 
out according to the Declaration of Helsinki and approved by 
the local ethics committee (Comitato Etico per la Sperimen-
tazione Clinica delle Province di Verona e Rovigo). Patients 
did not participate in any rehabilitation program during the 
follow-up period.
Treatment procedures
All patients were treated by the same physician. PRF was 
performed with the patient in the sitting position during the 
whole procedure. Before treatment, local anesthesia to the 
cutaneous and subcutaneous tissues was administered with 
2 mL of lidocaine 2%. A 22-gage, 100 mm, 5 mm active-tip 
radiofrequency needle was guided to the suprascapular notch 
under ultrasonography (linear transducer with a scanning 
frequency of 12 MHz).22 Anatomic landmarks were used for 
transducer position (the spine of the scapula, the acromion 
and the acromial end of the clavicle, and the coracoid process) 
and SSN localization (the trapezius muscle, the supraspinatus 
muscle, the supraspinous fossa, and the suprascapular and the 
spinoglenoid notch). The SSN was identified as a hyperechoic 
structure 3–4 cm deep and below the transverse scapular 
ligament in the scapular notch.23 Following elicitation of 
paresthesia response in the shoulder region to a 50 Hz, 1 ms, 
0.5 V sensorial stimulus and appropriate muscular response to 
a 2 Hz, 1 ms, 0.4 V motor stimulus, PRF treatment was applied 
at 485 kHz, 42 V, 20 ms, 42°C for 300 s (5 min; TherMedico 
NK1; schwa-medico GmbH, Ehringshausen, Germany).22,23 
Patients were discharged if no significant complications 
occurred (eg, pain, bleeding, or pneumothorax).
Evaluation procedure
All patients were evaluated before treatment (T0), at 4 weeks 
(T1), and at 16 weeks (T2) of follow-up. Patients remained 
seated during the evaluation procedure.
Primary outcome
The primary outcome was the VAS for pain, which consists 
of a 100 mm vertical line anchored with extremes of subjec-
tive pain.21
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Secondary outcomes
Secondary outcomes were the Modified Ashworth Scale 
(MAS), the shoulder passive range of motion (PROM), the Dis-
ability Assessment Scale (DAS), the Fugl-Meyer Assessment 
(FM), and the EuroQol-5 dimension questionnaire (EQ-5D).
The MAS was used to measure shoulder adductor 
muscles tone. This 6-point scale grades resistance to rapid 
passive stretch from 0 (no increase in muscle tone) to 5 
(joint is rigid).24,25 Shoulder flexion, extension, abduction, 
and external rotation PROM was measured using a handheld 
goniometer. Measurement sensitivity was arbitrarily set at 
5°.26 The DAS was used to evaluate the extent of functional 
impairment in the domains of patient hygiene, dressing, 
limb position, and pain as follows: 0, no disability; 1, mild 
disability; 2, moderate disability; and 3, severe disability.27,28 
The FM was used to evaluate the ability of the affected upper 
limb to perform selective movements. The maximum score 
on the FM upper limb section was 66, with subscores of 36 
for the upper arm, 10 for the wrist, 14 for the hand, and 6 
for coordination and speed of movement.29 Quality of life 
was assessed by the EQ-5D score on a visual scale from 
0 (worst imaginable health state) to 100 (best imaginable 
health state).30
Statistical analysis
Statistical analysis was carried out using the Statistical 
Package for Social Sciences for Macintosh, version 20.0 
(IBM Corporation, Armonk, NY, USA). The Wilcoxon 
signed-rank test was applied to compare differences in 
T1 vs T0 and T2 vs T0. The alpha level for significance 
was set at P<0.05. The Bonferroni correction was used 
for multiple comparisons, resulting in P<0.025 as the 
significance threshold.
Results
No adverse events occurred during the follow-up period. 
Table 1 presents the demographic and clinical characteristics 
of each patient.
Primary outcome
Significant improvements on the VAS after PRF treatment 
of the SSN were observed at T1 (P=0.023; Z=-2.27) and T2 
(P=0.023; Z=-2.27; Table 2).
Secondary outcomes
No significant improvement in the MAS score was found at 
T1 and T2. Significant improvements in the PROM of shoul-
der abduction were found at T1 (P=0.023; Z=-2.271) and 
T2 (P=0.024; Z=-2.264), shoulder flexion at T1 (P=0.024; 
Z=-2.25) and T2 (P=0.024; Z=-2.25), shoulder extension 
at T1 (P=0.02; Z=-2.33) and T2 (P=0.02; Z=-2.33), and 
external rotation at T1 (P=0.02; Z=-2.33) and T2 (P=0.02; 
Z=-2.33). Significant improvements in the DAS score 
for hygiene were found at T1 (P=0.024; Z=-2.25) and T2 
(P=0.024; Z=-2.25), dressing at T1 (P= 0.02; Z=-2.33) 
and T2 (P=0.024; Z=-2.264), and pain at T1 (P=0.024; 
Z=-2.264) and T2 (P=0.023; Z=-2.271) but for limb position. 
No significant improvement in FM was found at T1 and T2. 
Significant improvements in the EQ-5D were found at T1 
(P=0.024; Z=-2.264) and T2 (P=0.024; Z=-2.264; Table 2).
Discussion
The SSN provides 70% of sensory innervation to the shoulder 
joint.31 In chronic shoulder pain conditions, the afferent fibers 
of SSN may become entrapped by injured tissues or sensitized 
due to chronic pain.13,32 The SSN block provides temporary 
cessation of nociceptive information from the affected shoul-
der to CNS.12–16 Previous studies involving patients with HSP 
mainly focused on SSN block by combining local anesthet-
ics with cortisone.19,26,33–36 Early studies on this issue were 
contradictory. Lee and Khunadorn37 reported poor efficacy of 
SSN block on HSP relief, whereas Boonsong et al33 claimed 
that blocking the SSN was safe and effective for HSP. A later, 
properly sized, randomized controlled trial by Adey-Wakeling 
et al19 supported Boonsong et al’s findings about the superior-
ity of SSN block (1 mL of 40 mg/mL methylprednisolone + 
10 mL of 0.5% bupivacaine hydrochloride) on placebo for 
Table 1 Demographic and clinical characteristics of patients
Characteristics Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6
Age (years) 61 70 65 55 76 65
Sex Male Female Female Female Male Male
Time since stroke onset (years) 2 5 9 2 4 7
DN4 (score) 4 1 0 1 0 7
Pain medication Opioids NSAIDs NSAIDs Opioids Opioids Opioids
Abbreviations: DN4, Douleur Neuropathique in 4 Questions; NSAIDs, non-steroidal anti-inflammatory drugs.





reducing HSP intensity. The effectiveness of SSN block by 
combining local anesthetics with cortisone has been further 
confirmed in long-term chronic stroke patients with HSP.26 
With regard to our clinical practice, we usually treat (subacute 
or chronic) stroke patients with HSP by means of pain (oral) 
medication (mainly using non-steroidal anti-inflammatory 
drugs or opioids; Table 1). In the case of scant pain reduction, 
we then perform SSN block by combining local anesthetics 
with cortisone in order to obtain a relief of pain and conse-
quently facilitate neurorehabilitation. In the case of patients 
with short-lasting benefits after pharmacological SSN block, 
we provide ultrasound-guided SSN PRF treatment with a 
growing positive experience. Thus, from this point of view, 
the anesthetic SSN block might be considered also as a test for 
the effectiveness of treating SSN in patients with HSP. To the 
best of our knowledge, this is the first report about the effects 
of ultrasound-guided SSN PRF treatment in chronic stroke 
patients with HSP. As to the primary outcome, we observed 
a significant reduction in pain intensity up to 16 weeks after 
PRF treatment. This is in keeping with previous findings 
about the long-term (up to 6 months) effects of PRF SSN 
treatment.17 As to secondary outcomes, we observed that 
PRF treatment of the SSN might effectively lead to increased 
shoulder PROM, reduced joint disability, and improved 
quality of life up to 16 weeks after treatment. This is very 
relevant for rehabilitation. Indeed, while pain relief accompa-
nied improvement in PROM and quality of life, also reducing 
self-rated disability of the affected upper limb, our findings 
indicate the need for combining physical rehabilitation and 
antispastic drugs with analgesic strategies to reduce muscle 
tone and obtain functional improvements.38,39 Thus, PRF treat-
ment of the SSN might be proposed as a treatment option in 
stroke rehabilitation to facilitate shoulder mobilization and 
neuromotor techniques in patients with HSP.
To date, the mechanism of action of PRF treatment 
for pain relief is still an object of debate. From a physical 
point of view, the leading explanation for PRF effects is 
low electric field phenomenon that may induce a long-term 
depression of synaptic transmission.9 On the other hand, from 
a biological point of view, PRF seems to have effects also 
on cell morphology and pain signaling.9 In particular, PRF 
may enhance the descending noradrenergic and serotonergic 
inhibitory pathways, which are involved in pain modulation 
mechanisms.40 Furthermore, a neuromodulatory effect has 
been suggested via alternating gene expression (eg, c-Fos, 
ATF-3) in pain processing neurons by which PRF treatment 
may provide long-lasting pain relief.9,18,41 On these bases, 
in order to interpret our observations, we might suggest 








T1 vs T0, 
P value (Z)
T2 vs T0, 
P value (Z)
VAS (0–100 mm), mean (SD) 88.3 (7.5) 15.0 (12.2) 11.7 (9.8) 0.023 (-2.271)* 0.023 (-2.271)*
MAS shoulder adductors (0–5), 
median (IQR)
1.50 (1.00; 3.00) 1.00 (1.00; 2.00) 1.00 (1.00; 2.00) 0.083 (-1.732) 0.083 (-1.732)
Shoulder flexion PROM (degrees), 
mean (SD)
73.3 (28.8) 98.3 (28.6) 98.3 (28.6) 0.024 (-2.251)* 0.024 (-2.251)*
Shoulder extension PROM (degrees), 
mean (SD)
38.3 (4.1) 50.0 (1.5) 50.0 (2.7) 0.020 (-2.333)* 0.20 (-2.333)*
Shoulder abduction PROM (degrees), 
mean (SD)
71.7 (19.4) 105.0 (16.4) 106.7 (16.3) 0.023 (-2.271)* 0.024 (-2.264)*
Shoulder external rotation PROM (degrees), 
mean (SD)
34.2 (11.1) 45.8 (9.2) 45.8 (9.1) 0.020 (-2.333)* 0.20 (-2.333)*
DAS hygiene (0–3), median (IQR) 3.00 (2.75; 3.00) 1.00 (1.00; 2.00) 0.00 (0.00; 1.00) 0.024 (-2.251)* 0.024 (-2.251)*
DAS dressing (0–3), median (IQR) 2.50 (1.75; 3.00) 1.00 (0.75; 2.00) 0.00 (0.00; 1.00) 0.020 (-2.333)* 0.024 (-2.264)*
DAS limb position (0–3), median (IQR) 2.50 (0.75; 3.00) 0.50 (0.00; 1.00) 0.25 (0.00; 1.00) 0.041 (-2.041) 0.039 (-2,060)
DAS pain (0–3), median (IQR) 2.50 (2.00; 3.00) 0.00 (0.00; 1.25) 0.00 (0.00; 0.25) 0.024 (-2.264)* 0.023 (-2.271)*
FM upper limb, median (IQR) 8.50 (4.75; 21.00) 9.00 (4.75; 27.25) 9.00 (4.75; 27.25) 0.102 (-1.633) 0.102 (-1.633)
EQ-5D, median (IQR) 50.00 (37.50; 52.50) 70.00 (60.00; 80.00) 75.00 (67.50; 80.00) 0.024 (-2.264)* 0.024 (-2.264)*
Note: *Statistically significant after the Bonferroni correction (P<0.025).
Abbreviations: VAS, visual analog scale; SD, standard deviation; MAS, Modified Ashworth Scale; IQR, interquartile range; PROM, passive range of motion; DAS, Disability 
Assessment Scale; FM, Fugl-Meyer Assessment; EQ-5D, EuroQol-5 dimension questionnaire.
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a potential reduction in central sensitization secondary to 
a decrease in nociceptive stimuli, which would be in line 
with the hypothesized nociceptive and neuropathic nature 
of HSP.3 Moreover, we cannot exclude some kinds of neural 
tissue modification due to the PRF transient “heat spikes” 
(~45°C to 50°C around the needle tip, depending on the tis-
sue impedance as reported in the literature), whose ablative 
effect is unknown.10
This study has several limitations. First, it did not have 
a prospective design and the sample size was small. We 
estimated that a total of 27 patients would provide 90% 
power to detect a difference of 13 mm on the VAS (minimal 
clinically important difference) at the primary end point.42 
Second, there was no control group treated with placebo 
or other treatments (eg, intra-articular injection, local 
anesthesia, botulinum toxin, physical therapy) for shoulder 
pain. Third, no further ultrasound evaluation of the SSN 
was done after PRF. Thus, we have no information about 
any SSN structural change or nerve echo signal modifica-
tion after treatment.
Conclusion
Our observations support the use of ultrasound-guided SSN 
PRF treatment for HSP in chronic stroke patients. Future 
larger randomized controlled trials are desirable to produce 
new findings and possibly confirm ours about this issue.
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